Clean Science Q3 FY26 Earnings Analysis

- HALS segment expected to continue growing quarter-on-quarter, with 25% volume growth already seen in Q2 and plans to increase capacity utilization and revenues over the next two quarters. - Performance Chemicals Unit 1 capacity started with ~1,000 tons per annum, aiming for clearer customer demand next quarter before scaling further. - Performance Chemicals Unit 2 facility scheduled to start water trials in April 2026 and commercial production by June 2026, with a 3-year ramp-up expected. - The company targets INR 300 crore revenue from 10,000 tons capacity in Performance Chemicals by FY28. - Domestic market (mainly HALS) grew 13% in H1 FY26; still room to expand customer base with 70-75% capacity utilization for food-grade antioxidants. - Growth in new products and markets (US, Europe, Vietnam, Middle East, South Africa) expected as product acceptance improves. - Growth outlook for Q3 expected to be flat, with better growth anticipated in Q4 from legacy and new products. - Chinese market remains uncertain; strategy may be revised based on competitive landscape.

- HALS segment showing strong growth with 25% QoQ volume increase; expected to continue quarter-on-quarter growth, improving capacity utilization and revenues in next two quarters. - Performance Chemicals division expects commercial production starting June, ramp-up over ~3 years, with targeted revenue of INR 300 crores by FY 2028. - Sequential growth expected in Q3 and Q4, with Q4 growth anticipated from new and legacy products. - EBITDA guidance is cautious due to market uncertainties and tariff impacts; management prefers to wait 1-2 quarters for clearer outlook. - Product mix changes and competitive pressures in China may impact margins; efforts ongoing to counter pricing competition and increase wallet share. - Domestic market growth primarily driven by HALS product with ~50% market share in India. - Overall, company optimistic on expanding market share with new products and better pricing but conservative on near-term explicit EBITDA or EPS guidance.

- Clean Science invested approximately INR 150 crores in the subsidiary (CFCL) during H1 FY26. - Performance Chemical 1 facility is undergoing chemical trials with commercialization expected within 3-4 weeks. - Performance Chemical 2 facility water trials to start in April with commercial production anticipated by June; ramp-up expected over approximately 3 years. - Capacity expansion of some food-grade antioxidants has been successfully completed. - A new product (hydroxychloroquine-related) with an installed capacity of about 10,000 tons aims to generate approximately INR 300 crores revenue by FY28. - Commercialization of HALS 2020 and enrichment of the product portfolio with higher-grade HALS to drive volume growth. - The company is focusing on scaling up volumes gradually, with capacity utilization expected to improve over the next few quarters.

- The transcript from Q2 FY26 earnings call does not mention any current fundraising through debt or equity. - No specific plans or guidance are given regarding future fundraising activities. - The company focuses on commissioning and ramping up new projects and capacity expansions but does not discuss raising capital for these. - Siddharth Sikchi highlights progressing with commercial production and trials but refrains from commenting on funding strategies. - They prefer to assess the market and operational landscape before providing further financial guidance. In summary, as per the available transcript, there is no indication of current or immediate plans for fundraising via debt or equity.

- The company has started commercial samples for Performance Chemical One with less than 1,000 tons per annum of existing capacity utilized through refurbishment. - Full installed capacity for Performance Chemical One is about 10,000 tons, with revenue potential of around INR 300 crores by FY 2028. - Commercialization of barbituric acid successfully completed by repurposing existing facilities. - Capacity expansions have been done for some food-grade antioxidants. - Sales for Performance Chemical One and barbituric acid expected to gather momentum with increasing approvals and validations over coming quarters. - Sales volumes for HALS products growing sequentially at 25% volume and 34% value growth. - The company is focusing on growing exports in HALS as approvals from global markets are obtained. - While some pilot orders and sample dispatches are ongoing, mass volume offtake expected in Q4 FY26 and beyond.